PDT Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

PDT Partners’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-37,397	Closed	-$496K	–	566
2016 Q4	$496K	Sell	37,397 -125,303	-77%	-$2.14M	0.03%	400
2016 Q3	$3.86M	Buy	162,700 +87,600	+117%	+$2.35M	0.23%	166
2016 Q2	$2.16M	Buy	+75,100	New	+$2.45M	0.17%	193
2014 Q4	–	Sell	-101,089	Closed	-$2.4M	–	1273
2014 Q3	$2.4M	Buy	101,089 +76,288	+308%	+$1.95M	0.06%	363
2014 Q2	$744K	Buy	24,801 +147	+0.6%	+$3.97K	0.02%	802
2014 Q1	$651K	Sell	24,654 -500	-2%	-$12.5K	0.02%	826
2013 Q4	$632K	Sell	25,154 -15,190	-38%	-$339K	0.08%	326
2013 Q3	$827K	Buy	40,344 +14,233	+55%	+$294K	0.02%	841
2013 Q2	$521K	Buy	+26,111	New	+$463K	0.01%	1043

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

PDT Partners's IPXL Position: Q1 2017 in Review

PDT Partners sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 37,397 shares — an estimated $496K sold.

PDT Partners first reported a position in IPXL in Q2 2013 and held it in 9 quarters. The position peaked at $3.86M in Q3 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

PDT Partners reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
PDT Partners sold 37,397 Impax Laboratories, Inc. shares in Q1 2017, an estimated $496K.
PDT Partners first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 9 quarters.
PDT Partners's Impax Laboratories, Inc. position peaked at $3.86M in Q3 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on PDT Partners's 13F filing for Q1 2017, filed 15 May 2017.